Patents Assigned to Tactogen Inc.
  • INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION
    Publication number: 20250042900
    Abstract: The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as depression, anxiety, and trauma- and stressor-related disorders, comprising the indolizines having the structures disclosed herein.
    Type: Application
    Filed: September 23, 2024
    Publication date: February 6, 2025
    Applicant: TACTOGEN INC
    Inventor: Matthew J. Baggott
  • ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20250034102
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 30, 2025
    Applicant: TACTOGEN INC
    Inventor: Matthew Baggott
  • BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT
    Publication number: 20250019357
    Abstract: Salt morphic forms, morphic salt mixtures, and specified salt mixtures of pharmaceutically active benzofuran compositions are provided for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes salt morphic forms, morphic salt mixtures, and specified salt mixtures of benzofuran compounds, compositions thereof, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Application
    Filed: June 7, 2024
    Publication date: January 16, 2025
    Applicant: TACTOGEN INC
    Inventors: Matthew J. Baggott, Sean Jeffrey Lofthus, Xanthe Marie Renomeron De Leon, Aniruddh Singh, Connor James Hudgins
  • SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT
    Publication number: 20240335414
    Abstract: The present invention discloses specialized combinations and methods of use thereof that may be used for beneficially modulating the central nervous system and for treating central nervous system, inflammatory, and metabolic disorders.
    Type: Application
    Filed: June 7, 2024
    Publication date: October 10, 2024
    Applicant: TACTOGEN INC
    Inventors: Matthew J. Baggott, Sean Dalziel
  • INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT
    Publication number: 20240308999
    Abstract: The present invention discloses a compound, composition, method for modulating central nervous system activity, or method for treating central nervous system disorders, such as post-traumatic stress and adjustment disorders, comprising an indolizine-containing compound having a structure disclosed herein.
    Type: Application
    Filed: May 2, 2024
    Publication date: September 19, 2024
    Applicant: TACTOGEN INC
    Inventor: Matthew J. Baggott
  • Advantageous benzofuran compositions for mental disorders or enhancement
    Patent number: 11767305
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: September 26, 2023
    Assignee: Tactogen Inc
    Inventor: Matthew Baggott
  • ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230257347
    Abstract: Pharmaceutically active advantageous tryptamine compounds and their pharmaceutically acceptable salts, salt mixtures and pharmaceutically acceptable compositions are disclosed for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.
    Type: Application
    Filed: March 20, 2023
    Publication date: August 17, 2023
    Applicant: Tactogen Inc
    Inventor: Matthew Baggott
  • 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230183199
    Abstract: The present invention discloses 2-aminoindane Formulas I and II and their pharmaceutically acceptable salts, compositions and methods of use to modulate central nervous system activity, and to treat central nervous system disorders, such as post-traumatic stress, depression, anxiety, and adjustment disorders. In certain embodiments, the compounds of the present invention can be used for entactogenic therapy in counseling sessions, as needed periodically or consistently as necessary or desired.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 15, 2023
    Applicant: Tactogen Inc.
    Inventor: Matthew Baggott
  • ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230159487
    Abstract: Pharmaceutically active benzothiophene compounds and their pharmaceutically acceptable salts and salt mixtures and pharmaceutically acceptable compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.
    Type: Application
    Filed: January 5, 2023
    Publication date: May 25, 2023
    Applicant: TACTOGEN INC
    Inventor: Matthew Baggott
  • ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
    Publication number: 20230150963
    Abstract: Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 18, 2023
    Applicant: Tactogen Inc.
    Inventor: Matthew Baggott